%PDF-1.4
%
7 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
8 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
12 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
1 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
5 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
10 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
6 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
9 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
11 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
3 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
4 0 obj
<>>>/BBox[0 0 609.45 793.7]/Length 56>>stream
xs
w3T04PI2P0T5T0 q-,LBr44C@ i s
I-
endstream
endobj
14 0 obj
<>stream
application/pdf
10.1080/17512433.2017.1274651
en
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines
Sabina Paglialunga
Elliot Offman
Nita Ichhpurani
Thomas C. Marbury
Bruce H. Morimoto
Taylor & Francis
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017. doi:10.1080/17512433.2017.1274651
Kidney
clinical studies
glomerular filtration rate
chronic kidney disease
new drug application
drug development
end-stage renal disease
Journal
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
© 2017 Informa UK Limited, trading as Taylor & Francis Group
1751-2433
1751-2441
10
3
273
283
10.1080/17512433.2017.1274651
http://dx.doi.org/10.1080/17512433.2017.1274651
VoR
2017-02-21T11:16:35+05:30
Arbortext Advanced Print Publisher 11.0.3352/W Unicode
2017-03-01T09:38:58-08:00
2017-03-01T09:38:58-08:00
Kidney; clinical studies; glomerular filtration rate; chronic kidney disease; new drug application; drug development; end-stage renal disease
iText 4.2.0 by 1T3XT
uuid:0930b081-587c-4c99-a442-5246de848961
uuid:681dc294-fd7d-4cb7-b00e-7c0696c66b7a
2017-01-29truewww.tandfonline.com10.1080/17512433.2017.1274651www.tandfonline.comtrue2017-01-2910.1080/17512433.2017.1274651
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi y,
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS*
R
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 Bih lT
endstream
endobj
33 0 obj
<>stream
x+ |
endstream
endobj
34 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
35 0 obj
<>stream
x+ |
endstream
endobj
36 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
37 0 obj
<>stream
x+ |
endstream
endobj
38 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
40 0 obj
<>stream
xZI\G {ZHn`%ۀF%OU[tOo#|US^U6rH:~>ܿ<|s VUnޥZc}^>b7ck>N=p~ˣ2g8[8g~.svmqjcdy0!wס933uzI-!EQ,
Gm;qA%S93/̐\S
^&gi!Z@ׇv/뉱KZ>ަ%EO;P(k|x 4*U2Q9xWo_BNC^@R՟< 34è4
#'|[3UG@z ^t
?etJg64F|NIJn÷9Efq!֬>ѤX.SHH0'ju Fdz+)?Փ5p[`/t FzuM
eUu
p Վ( W-xȚ<f7UJ3DZ@:5ftڎ憄8q:Н;YYak,,
Vv\Nl4o}#oEfMX0=a-kMJS e 23iD&:StŠ8DH+H@ɢPЗa,È7.Uu :!~B)xÀ `) Č܀ى^!/`)Eb$0Gvdф{ j]">c5y%[5B¾5:)]:~wKx;ji71uj1un+kO$6̭2+6b܁©܋kVyPdl2N.c[H\pi<=wK/fxT
a$".BRuRydQ^j#OePt|z~ *=GӼӞ:A.vm#C;zXO"CtС:̯U-WLHO~z*l;)0j:]:POfv鐮:#[f $\Hv?Y4bm&]aGzq #ɋ|rhj~W/J˟3ݠ*,*rsXܳi*v+9BjTA^.
d)5a/0dž2z3 ހ!l݈.c#PJ5w"fw-h0"I5
2v Џ* oY7sV'6aSnc&"Wpۮ{b\(LT6 N77X?!n@RaǞ8ݶ!U~n(NOQZd.ՓGëe"^(SeJC6s
A5s뮁*\6!X q\!L3;+EXԈˢE6;P1zB/͙Uƨc ;, 6X5ꄁL*MVv8s ?܇g"(;xŚtb4L4ykUEHRCljđvahFdy^Z96$`#]5&Ѡ-tm绹bF|s44)aVG%|8];;[ߖAt%,C6wڵufE复_?"%d-^Db+"XՉfe OKk~ĂDS:YӿNA2!R)YZmw!}<]kA7ٷwZ%>ƮF=9!Ͳ~Z =